We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

QuidelOrtho

Develops, manufactures and markets rapid diagnostic tests that focus on infectious diseases, reproductive health, and... read more Featured Products: More products

Download Mobile App




YKL-40 Associated with Severity in Patients with Necrotizing Soft-Tissue Infection

By LabMedica International staff writers
Posted on 28 Oct 2021
Necrotizing soft-tissue infection (NSTI) is a rare, severe and fast-progressing bacterial infection. More...
NSTI can be caused by a myriad of aerobic, anaerobic and facultative anaerobic bacteria, but predominantly by Group A Streptococcus in monomicrobial infections.

YKL-40, also called chitinase-3-like-1 protein, may be an attractive prognostic biomarker in NSTI. YKL-40 is an acute phase protein secreted by several of immune cells, including macrophages, neutrophils and endothelial cells. Proteomic analysis has indicated YKL-40 as a promising biomarker in patients with severe sepsis and septic shock.

Clinical Scientists at the Copenhagen University Hospital (Copenhagen, Denmark) investigated the association between plasma YKL-40 and 30-day mortality in patients with NSTI, and assessed its value as a marker of disease severity. They determined plasma YKL-40 levels in 161 patients with NSTI and 65 age-sex matched controls upon admission and at day 1, 2 and 3.

Patient had blood samples collected into ethylenediaminetetraacetic acid (EDTA) sample tubes upon admission (baseline), and at the following three days (all between 8 AM and 12 AM). Plasma YKL-40 was quantified in duplicates by commercial enzyme-linked immunosorbent (ELISA) technique (Quidel, San Diego, CA, USA) at each of the four time points. The minimal detectable limit for YKL-40 was 10 ng/mL.

The investigators reported that baseline plasma YKL-40 was 1,191 ng/mL in patients with NSTI compared with 40 ng/mL in controls. YKL-40 was found to be significantly higher in patients with septic shock (1,942 versus 720 ng/mL), and in patients receiving renal-replacement therapy (2,382 versus 1,041 ng/mL). YKL-40 correlated with Simplified Acute Physiology Score II. Baseline YKL-40 above 1,840 ng/mL was associated with increased risk of 30-day mortality in age-sex-comorbidity adjusted analysis (OR 3.77), but after further adjustment for Simplified Acute Physiology Score II no association was found between YKL-40 and early mortality.

Plasma YKL-40 was significantly higher in patients with NSTI compared to controls at admission, and at day 1 and 2. Plasma YKL-40 at admission was significantly higher among 45 patients infected with mono or polymicrobial Group A Streptococcus in blood and/or tissue (2,338 ng/mL) compared to 104 other types of NSTI (1,246 ng/mL). However, this was not observed at day 1, 2 and 3. No microbial findings were observed in 12 patients.

The authors concluded that high plasma YKL-40 levels were associated with disease severity and risk of death in patients with NSTI. However, YKL-40 is not an independent predictor for 30-day mortality. The study was published on October 9, 2021 in the journal BMC Infectious Diseases.

Related Links:
Copenhagen University Hospital
Quidel




New
Gold Member
Automatic CLIA Analyzer
Shine i9000
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A blood biomarker test offers a clearer prognosis after cardiac arrest (Photo courtesy of Adobe Stock)

Blood Biomarker Improves Early Brain Injury Prognosis After Cardiac Arrest

After a cardiac arrest, many patients remain unconscious for days, leaving doctors and families facing uncertainty about whether meaningful recovery is possible. Current tools to assess brain damage, including... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.